These reviews have led to reports from the Australian National Drug Strategy (Hall 1994), the Netherlands Health Council (Gezondheidsraad 1996), the British Medical Association (1997), the American Medical Association (1997), a House of Lords (UK) Select Committee (1998), the Royal Pharmaceutical Association in the UK (1999), the US National Academy of Sciences Institute of Medicine (Joy 1999), and the WHO (Hartel 1999).
Ces examens ont mené à la publication de rapports rédigés par le Australian National Drug Strategy (Hall 1994), le Conseil de la santé des Pays-Bas (Gezondheidsraad 1996), la British Medical Association (1997), la American Medical Association (1997, un House of Lords Select Committee (Royaume-Uni) (1998), la Royal Pharmaceutical Association au Royaume-Uni (1999), l’Institute of Medicine de la U.S. National Academy of Sciences (Joy 1999) et l’OMS (Hartel 1999).